Research & Development
FDA grants priority review to Genentech's Gazyva for primary membranous nephropathy
15 July 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Wednesday that the US Food and Drug Administration (FDA) has granted priority re...
AstraZeneca signs global licence deal with Dizal for lung cancer drug Zegfrovy
14 July 2026 - Biopharmaceutical company AstraZeneca PLC (STO: AZN; LON: AZN; NYSE: AZN) announced on Tuesday that it has agreed an exclusive worldwide licence with China's Dizal Pharmaceutical C...
Summit Therapeutics sells Phase III antibiotic asset ridinilazole to Biossil
14 July 2026 - Biopharmaceutical oncology company Summit Therapeutics Inc (NASDAQ:SMMT) on Tuesday announced an agreement to sell ridinilazole, an investigational Phase III precision antibiotic, to To...
European Commission approves Erbitux combination for first-line BRAF V600E-mutant mCRC
14 July 2026 - US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD outside the US and Canada, announced on Tuesday that the European Commission has approved an updated label for Erbi...
US FDA accepts BioMarin's sNDA for full approval of VOXZOGO (vosoritide) for children with achondroplasia
14 July 2026 - Rare disease biotechnology company BioMarin Pharmaceutical Inc (Nasdaq:BMRN) announced on Monday that the US Food and Drug Administration (FDA) has accepted the company's supplemen...
Eisai reports new data showing etalanetug reduces Alzheimer's Disease tau tangle‑specific biomarker
13 July 2026 - Japanese pharmaceutical company Eisai Co., Ltd. (TYO: 4523) on Monday reported new findings showing that its investigational anti-MTBR antibody etalanetug (E2814) reduced levels of plas...